Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Domenico Russo, MD, Giovanni Martinelli, Michele Malagola, Valeria Cancelli, Cristina Skert, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Diamante Turri, Salvatore Mirto, MD, Marco Gobbi, MD, Ivana Pierri, MD, Umberto Vitolo, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, MD, Francesco Di Raimondo, MD, Fabio Stagno, MD PhD, Giuliana Alimena, Massimo Breccia, MD, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, MD, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, MD, Giuseppina Nicolini, Paolo de Fabritiis, MD, Elisabetta Abruzzese, MD, Renato Fanin, MD, Mario Tiribelli, MD, Piero Galieni, MD, Catia Bigazzi, Giorgina Specchia, MD, Emanuele Angelucci, Emilio Usala, MD, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, MD PhD, Monia Lunghi, MD, Francesco Lauria, MD, Monica Bocchia, MD, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, Giovanni Quarta, MD, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Mario Cesana, Gianantonio Rosti

Blood (2014) 124 (21): 1794.

https://doi.org/10.1182/blood.V124.21.1794.1794

Published: 2014

Journal Articles

Circulating Plasma Cells in Newly Diagnosed Symptomatic Multiple Myeloma As a Prognostic Marker for Patients with Standard-Risk Cytogenetics

Davide Vagnoni, Fosco Travaglini, Stefano Angelini, Alessia Dalsass, Francesca Mestichelli, Mario Angelini, Valerio Pezzoni, Annalisa Natale, Miriana Ruggieri, Catia Bigazzi, Emanuela Troiani, Sadia Falcioni, Serena Mazzotta, Piero Galieni

Blood (2014) 124 (21): 3353.

https://doi.org/10.1182/blood.V124.21.3353.3353

Published: 2014

Journal Articles

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Blood (2013) 121 (26): 5138–5144.

https://doi.org/10.1182/blood-2013-01-480194

Published: 2013

Includes: Supplemental data

Journal Articles

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli, MD, Chiara Colombi, Michele Malagola, Cristina Skert, MD, Simona Soverini, Ilaria Iacobucci, PhD, Diamante Turri, MD, Salvatore Mirto, Marco Gobbi, MD, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, MD, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, MD, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, M.D., Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, MD, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Cesana, Gianantonio Rosti, MD

Blood (2011) 118 (21): 1682.

https://doi.org/10.1182/blood.V118.21.1682.1682

Published: 2011

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Domenico Russo, Gianantonio Rosti, Giovanni Martinelli, Michele Malagola, Salvatore Mirto, Diamante Turri, Marco Gobbi, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, Francesco Di Raimondo, M.D., Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, MD, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Vincenzo Liso, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, MD, Monia Lunghi, Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, MD, Giovanni Quarta, Mariella Girasoli, Alberto Bosi, Valeria Santini, Giuseppe Fioritoni, Roberto Di Lorenzo, Chiara Colombi, Miriam Fogli, Marilina Amabile, Nicoletta Testoni, Antonio De Vivo, Michele Baccarani

Blood (2009) 114 (22): 860.

https://doi.org/10.1182/blood.V114.22.860.860

Published: 2009

NARROW

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Circulating Plasma Cells in Newly Diagnosed Symptomatic Multiple Myeloma As a Prognostic Marker for Patients with Standard-Risk Cytogenetics

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Email alerts

ASH Publications

American Society of Hematology

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Circulating Plasma Cells in Newly Diagnosed Symptomatic Multiple Myeloma As a Prognostic Marker for Patients with Standard-Risk Cytogenetics

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only